NLRP3 and myocardial infarction: Recently, adapters that inhibit the NLRP3 inflammasome and inhibitors that utilize NLRP3 inflammasomes were shown to be beneficial in reducing the myocardial infarct size and improving cardiac function in animal studies, and early clinical trials are expected to show their effectiveness [126].